Zoetis Inc. (NYSE:ZTS) Shares Purchased by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 18.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,997 shares of the company’s stock after purchasing an additional 628 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Zoetis were worth $781,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. First Personal Financial Services bought a new stake in shares of Zoetis during the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis during the third quarter valued at approximately $33,000. Quarry LP lifted its stake in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC acquired a new stake in shares of Zoetis during the first quarter valued at approximately $43,000. Finally, Fortitude Family Office LLC raised its holdings in shares of Zoetis by 1,387.5% during the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.2 %

Shares of ZTS opened at $173.95 on Wednesday. The business has a 50-day moving average of $188.00 and a 200 day moving average of $179.93. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market cap of $78.48 billion, a P/E ratio of 32.70, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.36 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. Zoetis’s dividend payout ratio is presently 32.33%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ZTS shares. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.